Amgen Expands R&D Footprint with New Hyderabad Innovation Hub
Event summary
- Amgen will open a Science & Innovation Center in Hyderabad's Genome Valley, operational by 2027.
- The facility expands Amgen’s global R&D network to eight sites, integrating discovery chemistry, drug metabolism, and precision medicine capabilities.
- Hyderabad’s life sciences ecosystem and STEM talent pool drive Amgen’s decision to deepen its India presence.
- The center will complement Amgen’s existing Hyderabad site, enhancing wet-lab science with digital innovation.
The big picture
Amgen’s new Hyderabad center underscores the growing trend of global biotech firms leveraging India’s scientific talent and cost advantages for high-value R&D. The move aligns with broader industry shifts toward decentralized innovation hubs, reducing reliance on traditional U.S.-centric research models. With Genome Valley emerging as a life sciences hotspot, Amgen’s expansion could signal a new phase of outsourcing—or rather, strategic co-location—of drug discovery efforts.
What we're watching
- Execution Risk
- Whether Amgen can seamlessly integrate Hyderabad’s capabilities with its global R&D network.
- Talent Competition
- How Amgen will attract and retain top scientific talent in Hyderabad’s competitive life sciences market.
- Regulatory Dynamics
- The pace at which India’s regulatory environment evolves to support cutting-edge biotech research.
Related topics